[Myelodysplastic syndrome].
Myelodysplastic syndrome is a hematopoietic stem cell disorder characterized by ineffective hematopoiesis and leukemic progression. Accumulation of various kinds of genetic alterations in oncogene and tumor suppressor gene develops and accelerates the disease. Recently, alpha-catenin gene has been identified as a candidate gene in the 5q- anomaly. Diagnostic criteria have been updated by Valent et al. WHO classification has become popular and WHO classification-based prognostic scoring system will be employed to evaluate prognosis. In our country, clinical studies on vitamin K2+D3 and cyclosporine A were conducted in low-risk patients, and their efficacy and safety have been reported. In US, molecular-targeting therapy with lenalidomide or demethylase is approved by FDA.
Mitani
Kinuko
K
Department of Hematology, Dokkyo Medical University School of Medicine.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D002762:Cholecalciferol / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D000077209:Decitabine; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D011379:Prognosis; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D024482:Vitamin K 2 / Q000627:therapeutic use; D014944:World Health Organization; D051178:alpha Catenin / Q000235:genetics
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D051178:alpha Catenin; D024482:Vitamin K 2; D002762:Cholecalciferol; D013792:Thalidomide; D000077209:Decitabine; D016572:Cyclosporine; D000077269:Lenalidomide; D001374:Azacitidine